Clinical trials in triple negative breast cancer
作者： Katherine E. Reeder-Hayes , Lisa A. Carey , William M. Sikov
DOI: 10.3233/BD-2010-0310
关键词:
摘要: Abstract Triple negative breast cancer (TNBC) is an aggressive subtype of the disease against which targeted therapies that significantly improve prognosis for hormone receptor-positive and HER2-overexpressing cancers are ineffective. This article summarizes our current understanding biology TNBC as it relates to efficacy standard investigational therapies. It reviews promising preliminary results have been achieved with chemotherapeutic agents including platinum analogs inhibit DNA repair by targeting poly ADP-ribose polymerase (PARP), while anti-angiogenic those target epidermal growth factor receptor (EGFR) had more limited success. Agents a number other pathways appear influence biologic aggressiveness TNBC, src PI3K, in early stage clinical trials. As we learn about its characteristics determine treatment response resistance, should become better able select appropriate biologically defined patient subgroups, reduce burden this disease.
sci-hub.se 参考文章(111)
Kenneth C. Chu, Charisee A. Lamar, Harold P. Freeman, Racial disparities in breast carcinoma survival rates Cancer. ,vol. 97, pp. 2853- 2860 ,(2003) , 10.1002/CNCR.11411
Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457
Mark Ator, Susan Jones-Bolin, Weihua Wan, Kathryn Hunter, Andres Klein-Szanto, Robert Hudkins, Sonya Pritchard, Craig Dionne, Sheila J. Miknyoczki, Sankar Chatterjee, Bruce Ruggeri, Ronald Bihovsky, Hugh Zhao, Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor Molecular Cancer Therapeutics. ,vol. 2, pp. 371- 382 ,(2003)
J. O'Shaughnessy, D. Miles, R. J. Gray, V. Dieras, E. A. Perez, R. Zon, J. Cortes, X. Zhou, S. Phan, K. Miller, A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Journal of Clinical Oncology. ,vol. 28, pp. 1005- 1005 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.1005
L. A. Carey, H. S. Rugo, P. K. Marcom, W. Irvin, M. Ferraro, E. Burrows, X. He, C. M. Perou, E. P. Winer, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer Journal of Clinical Oncology. ,vol. 26, pp. 1009- 1009 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.1009
Paul O Hassa, Michael O Hottiger, The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases Frontiers in Bioscience. ,vol. 13, pp. 3046- 3082 ,(2008) , 10.2741/2909
R. A. Dent, G. J. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. J. McCarthy, C. F. Singer, E. S. Lowe, K. Kemsley, J. Carmichael, Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. Journal of Clinical Oncology. ,vol. 28, pp. 1018- 1018 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.1018
S. J. Isakoff, B. Overmoyer, N. M. Tung, R. S. Gelman, V. L. Giranda, K. M. Bernhard, K. R. Habin, L. W. Ellisen, E. P. Winer, P. E. Goss, A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 28, pp. 1019- 1019 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.1019
R. Plummer, P. Lorigan, J. Evans, N. Steven, M. Middleton, R. Wilson, K. Snow, R. Dewji, H. Calvert, First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM) Journal of Clinical Oncology. ,vol. 24, pp. 8013- 8013 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.8013
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer, Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 115, pp. 115- 121 ,(2009) , 10.1007/S10549-008-0055-9